期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

普瑞巴林用于糖尿病痛性神经病变的疗效和安全性 被引量：7

Efficacy and safety of pregabalin in patients with diabetic painful neuropathy
原文传递
导出
摘要 目的:研究普瑞巴林用于糖尿病痛性神经病变的疗效和安全性。方法:52例糖尿病痛性神经病变患者随机分2组,对照组服用羟考酮控释片,试验组服用普瑞巴林胶囊,用药2周。评估治疗前后疼痛缓解程度和不良反应的发生情况。结果:对照组和试验组的有效率分别为56.0%和77.8%(P<0.05),试验组的镇痛效果优于对照组。治疗期间未见严重并发症。结论:普瑞巴林治疗糖尿病痛性神经病变疼痛安全有效。 Objective： To evaluate the efficacy and safety of pregabalin in patients with diabetic painful neuropathy.Methods： Fifty-two patients with diabetic painful neuropathy were enrolled and randomly divided into 2 groups.After they took either controlled-release oxycodone or pregabalin,pain relief and adverse reactions were evaluated.Results： After two-week treatment with oxycodone and pregabalin,the overall effective rates were 56.0% and 77.8%（P0.05）,respectively.The pain reliving effect in pregabalin group was better than that in oxycodone group.Severe adverse reactions did not occur.Conclusion： Pregabalin is effective and safe for treating patients with diabetic painful neuropathy.
作者 孙德海 纪春梅 马玲 姜长林
机构地区 黑龙江大庆油田总医院疼痛门诊
出处 《中国新药杂志》 CAS CSCD 北大核心 2011年第14期1302-1304,共3页 Chinese Journal of New Drugs
关键词 普瑞巴林 糖尿病痛性神经病变 神经病理性疼痛 疗效 pregabalin diabetic painful neuropathy neropathic pain efficacy
分类号 R587.2 [医药卫生—内分泌]
  • 相关文献

参考文献12

  • 1GORE M, BRANDENBURG NA, HOFFMAN DL, et al. Burden of illness in painful diabetic peripheral neuropathy : the patients' perspectives [ J ]. Pain,2006,7 ( 12 ) : 892 - 900.
  • 2SILLS GJ. The mechanisms of action of gahapentin and pregaba- lin [ J ]. Curr Opin Pharmacol,2006,6 ( 1 ) : 108 - 113.
  • 3BIAN F, LI Z, OFFORD J,et al. Calcium channel alpha2-deha type 1 subunit is themajorbinding protein for pregabalin in neoco- rtex, hippocampus, amygdala, and spinal cord: an cx vivo auto radiographic study in alpha2-delta type 1 genetically modified mice[J].Brain Res, 2006, 1075(1): 68-80.
  • 4JOSHI I, TAYLOR CP. Pregabalin action at a model synapse: binding to presynaptic calcium channel alpha2-deha subunit re- duces in mice [ J ]. Eur J Pharmacol, 2006 553(1 -3) : 82 -88.
  • 5MCCLELLAND D, EVANS RM, BARKWORTH L,et al. A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats [ J ]. BMC Pharmacol, 2004, 4 : 14.
  • 6INDMARCH I, TRICK L, RIDOUT F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of he cognitive and psychomotor profile of pregabalin in healthy volun- teers [ J ]. Psychopharmacology ( Berl), 2005, 183 ( 2 ) : 133 - 143.
  • 7RICHTER RW, PORTENOY R, SHARMA U,et al. Relief of painful diabetic peripheral Neuropathy with pregabalin: a ran- domized, placebo-controlled trial [ J ]. Pain, 2005, 6 ( 4 ) : 253 - 260.
  • 8CROFFORD LJ, ROWBOTHAM MC,MEASE PJ,et al. Pregaba- lin for the treatment of fibromyalgia syndrome: results of a ran- domized, double-blind, placebo-controlled trial [ J ]. Arthritis Rheum, 2005, 52(4): 1264-1273.
  • 9TARRIDE JE, GORDON A, VERA-LLONCH M,et al. Cost ef- fectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective [ J ]. Clin Ther, 2006, 28 (11) : 1922 -1934.
  • 10FREYNHAGEN R, BUSCHE P, KONRAD C,et al. Effective- ness and time to onset of pregabalin in patients with neuropathic pain[ J]. Schmerz, 2006, 20(4): 285- 288, 290- 292.

同被引文献61

  • 1BARON R, BRUNNMOLLER U, BRASSER M, et al. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study[ J ]. Eur J Pain, 2008, 12 ( 7 ) :850 - 858.
  • 2OPSTELTEN W, ZUITHOFF NP, VAN ESSEN GA, et al. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study [ J]. Pain, 2007, 132(Suppl 1) : S52-S59.
  • 3JOHNSON RW, BOUHASSIRA D, KASSIANOS G, et al. The impact of herpes zostcr and post-herpetic neuralgia on quality-of-life[J]. BMCMed, 2010, 21(8): 37 -50.
  • 4DURKIN B, PAGE C, GLASS P. Pregabalin for the treatment of postsurgical pain [J]. Expert Opin Pharmacother, 2010, 11 (16) : 2751 -2755.
  • 5GALLUZZI KE. Managing neuropathic pain[ J ]. J Am Osteopath Assoc, 2007, 107( Suppl 6) : ES39 - ES48.
  • 6JOSHI I, TAYLOR CP. Pregabalin action at a model synapse: binding to presynaptic calcium channel, alpha2-delta subunit reduces neurotransmission in mice [ J ]. Eur J Pharmacol, 2006, 553(1 -3): 82 -88.
  • 7SEVENTER R, FEISTER HA, YOUNG JP, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia:a 13-week, randomized trial[ J]. Curr Med Res Opin, 2006, 22(2) :375 - 384.
  • 8OWEN RT. Pregabalin: is efficacy,safety and tolerability profile in generalized anxiety[ J]. Drugs Today(Barc), 2007, 43 (9) : 601 -610.
  • 9RANDINITIS EJ, POSVAR EL, ALVEY CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function[J]. JClinPharmacol, 2003, 43(3): 277-283.
  • 10TASSONE DM, BOYCE E, GUYER J, et al. Pregabalin: a novel γ-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders[ J]. Clin Ther, 2007, 29(1) :26 -48.

引证文献7

二级引证文献45

中国新药杂志
2011年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部